SCP Investment’s Heron Therapeutics HRTX Stock Holding History

SCP Investment’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-20,000	Closed	-$519K	–	64
2018 Q4	$519K	Sell	20,000 -40,000	-67%	-$1.1M	0.48%	25
2018 Q3	$1.9M	Sell	60,000 -26,800	-31%	-$998K	1.54%	23
2018 Q2	$3.37M	Buy	+86,800	New	+$2.76M	1.67%	18

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

SCP Investment's HRTX Position: Q1 2019 in Review

SCP Investment sold out of Heron Therapeutics (HRTX) in Q1 2019, closing a stake of 20,000 shares — an estimated $519K sold.

SCP Investment first reported a position in HRTX in Q2 2018 and held it in 3 quarters. The position peaked at $3.37M in Q2 2018. 198 funds tracked by Wall St. Rank hold HRTX as of Q1 2019.

SCP Investment reported no remaining Heron Therapeutics position as of Q1 2019 after selling out during the quarter.
SCP Investment sold 20,000 Heron Therapeutics shares in Q1 2019, an estimated $519K.
SCP Investment first reported a position in Heron Therapeutics in Q2 2018 and held it in 3 quarters.
SCP Investment's Heron Therapeutics position peaked at $3.37M in Q2 2018.
198 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2019.

Based on SCP Investment's 13F filing for Q1 2019, filed 15 May 2019.